RO-7428731

N/A

Report date: 2026/03/19 17:18:36

Base Information

Drug NameRO-7428731

Drug Alias NameEGFRvIII X CD3 (Roche)RO-7428731RG-6156

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-EGFRvIIIAnti-CD3

TargetsEpidermal growth factor receptor variant IIIT cell surface glycoprotein CD3

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesDenmark +[5]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ltd

China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A